Home » USA Broker Ratings » DexCom – Consenus Indicates Potential -7.9% Downside

DexCom – Consenus Indicates Potential -7.9% Downside

DexCom with ticker code (DXCM) now have 16 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 245 and 185 with a mean TP of 211. Given that the stocks previous close was at 229.18 this would indicate that there is a downside of -7.9%. The 50 day moving average now sits at 189.35 and the 200 moving average now moves to 159.45. The company has a market capitalisation of $20,543m. Find out more information at: http://www.dexcom.com

DexCom, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient’s mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom was founded in 1999 and is headquartered in San Diego, California.

Join us on our new LinkedIn page

Follow us on LinkedIn